Introduction Spontaneous Remission the Spectrum of Self-Repair by Caryle Hirshberg
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Geriatric Depression Diagnosis and Treatment
Geriatric Depression Diagnosis and Treatment David Mansoor, MD Assistant Professor of Psychiatry OHSU/PVAMC March 2020 Disclosures • None Objectives • Introduction / Epidemiology • Assessment • Differential Diagnosis & Other Considerations – Late onset depression – Vascular depression – Depression in Alzheimer’s • Treatment Introduction & Epidemiology Introduction • Not a normal part of aging • Prevalence is lower than in community dwelling elderly than in younger adult population 12-month prevalence of MDE among US Adults (2012) • 80% are treated in primary care clinics Introduction • Community dwelling elderly populations – prevalence about 2-4% • More common in medical settings – 9% of chronically ill – 20-40% of hospitalized elders – 30-50% of nursing home residents – Highest in geriatric psych units (>60% of admissions) • Most common psychiatric disorder in the elderly Blazer et al. The Gerontologist. 1987 Introduction • Personal suffering and poor quality of life – Decreased physical, cognitive, and social function • Amplifies disabilities – Poorer recovery from hip fracture1 – Develops in up to 30% of stroke survivors – Cognition, physical strength, gait, balance, ADLs – Less likely to comply with cardiac rehab and have prolonged recovery times2 – Risk factor for developing DM, associated with worse outcomes3 1. BMC Geriatrics June 2013 2. J Cardiopulm Rehabil Prev. 2009 Nov-Dec;29(6):358-64 3. Am J Med. 2008 Nov; 121(11 Suppl 2): S8–15. Introduction • Increased mortality from medical illness – Risk factor for CHD (Arch Intern -
The AML Guide Information for Patients and Caregivers Acute Myeloid Leukemia
The AML Guide Information for Patients and Caregivers Acute Myeloid Leukemia Emily, AML survivor Revised 2012 Inside Front Cover A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) wants to bring you the most up-to-date blood cancer information. We know how important it is for you to understand your treatment and support options. With this knowledge, you can work with members of your healthcare team to move forward with the hope of remission and recovery. Our vision is that one day most people who have been diagnosed with acute myeloid leukemia (AML) will be cured or will be able to manage their disease and have a good quality of life. We hope that the information in this Guide will help you along your journey. LLS is the world’s largest voluntary health organization dedicated to funding blood cancer research, advocacy and patient services. Since the first funding in 1954, LLS has invested more than $814 million in research specifically targeting blood cancers. We will continue to invest in research for cures and in programs and services that improve the quality of life for people who have AML and their families. We wish you well. Louis J. DeGennaro, PhD President and Chief Executive Officer The Leukemia & Lymphoma Society Inside This Guide 2 Introduction 3 Here to Help 6 Part 1—Understanding AML About Marrow, Blood and Blood Cells About AML Diagnosis Types of AML 11 Part 2—Treatment Choosing a Specialist Ask Your Doctor Treatment Planning About AML Treatments Relapsed or Refractory AML Stem Cell Transplantation Acute Promyelocytic Leukemia (APL) Treatment Acute Monocytic Leukemia Treatment AML Treatment in Children AML Treatment in Older Patients 24 Part 3—About Clinical Trials 25 Part 4—Side Effects and Follow-Up Care Side Effects of AML Treatment Long-Term and Late Effects Follow-up Care Tracking Your AML Tests 30 Take Care of Yourself 31 Medical Terms This LLS Guide about AML is for information only. -
Cancer Treatment and Survivorship Facts & Figures 2019-2021
Cancer Treatment & Survivorship Facts & Figures 2019-2021 Estimated Numbers of Cancer Survivors by State as of January 1, 2019 WA 386,540 NH MT VT 84,080 ME ND 95,540 59,970 38,430 34,360 OR MN 213,620 300,980 MA ID 434,230 77,860 SD WI NY 42,810 313,370 1,105,550 WY MI 33,310 RI 570,760 67,900 IA PA NE CT 243,410 NV 185,720 771,120 108,500 OH 132,950 NJ 543,190 UT IL IN 581,350 115,840 651,810 296,940 DE 55,460 CA CO WV 225,470 1,888,480 KS 117,070 VA MO MD 275,420 151,950 408,060 300,200 KY 254,780 DC 18,750 NC TN 470,120 AZ OK 326,530 NM 207,260 AR 392,530 111,620 SC 143,320 280,890 GA AL MS 446,900 135,260 244,320 TX 1,140,170 LA 232,100 AK 36,550 FL 1,482,090 US 16,920,370 HI 84,960 States estimates do not sum to US total due to rounding. Source: Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute. Contents Introduction 1 Long-term Survivorship 24 Who Are Cancer Survivors? 1 Quality of Life 24 How Many People Have a History of Cancer? 2 Financial Hardship among Cancer Survivors 26 Cancer Treatment and Common Side Effects 4 Regaining and Improving Health through Healthy Behaviors 26 Cancer Survival and Access to Care 5 Concerns of Caregivers and Families 28 Selected Cancers 6 The Future of Cancer Survivorship in Breast (Female) 6 the United States 28 Cancers in Children and Adolescents 9 The American Cancer Society 30 Colon and Rectum 10 How the American Cancer Society Saves Lives 30 Leukemia and Lymphoma 12 Research 34 Lung and Bronchus 15 Advocacy 34 Melanoma of the Skin 16 Prostate 16 Sources of Statistics 36 Testis 17 References 37 Thyroid 19 Acknowledgments 45 Urinary Bladder 19 Uterine Corpus 21 Navigating the Cancer Experience: Treatment and Supportive Care 22 Making Decisions about Cancer Care 22 Cancer Rehabilitation 22 Psychosocial Care 23 Palliative Care 23 Transitioning to Long-term Survivorship 23 This publication attempts to summarize current scientific information about Global Headquarters: American Cancer Society Inc. -
MINI-REVIEW New Definition of Remission in Childhood Acute
Leukemia (2000) 14, 783–785 2000 Macmillan Publishers Ltd All rights reserved 0887-6924/00 $15.00 www.nature.com/leu MINI-REVIEW New definition of remission in childhood acute lymphoblastic leukemia C-H Pui1,2,3 and D Campana1,3 Departments of 1Hematology-Oncology and 2Pathology, St Jude Children’s Research Hospital; and 3The University of Tennessee College of Medicine, Memphis, Tennessee, USA The extent of clearance of leukemic cells from the blood or patients.5,6 Either method is at least 100-fold more sensitive bone marrow during the early phase of therapy is an inde- than morphologic examination of marrow specimens and con- pendent prognostic factor in acute lymphoblastic leukemia 4 (ALL). Several methods are available to measure the minimal sistently identifies one leukemic cell among 10 or more nor- residual disease (MRD) remaining after initial intensive chemo- mal bone marrow cells. Recent demonstration of the inde- therapy. The most promising are flow cytometric detection of pendent prognostic significance of MRD levels in remission aberrant immunophenotypes and polymerase chain reaction bone marrow samples using these methods7–9 provided the analysis of clonal antigen-receptor gene rearrangements. When impetus to redefine complete remission in patients with ALL.10 applied together, these techniques enable one to monitor MRD However, several critical issues must be addressed before in virtually all cases of ALL. Patients who achieve an ‘immuno- logic’ or ‘molecular’ remission (ie leukemic involvement of MRD determinations can be routinely considered in clinical ,0.01% of nucleated bone marrow cells at the end of remission decision making. induction therapy) are predicted to have a better clinical out- come than patients whose remission is defined solely by mor- phologic criteria. -
Definition of Cure for Hodgkin's Disease
[CANCER RESEARCH 31, 1828-1833, November 1971] Definition of Cure for Hodgkin's Disease Emil Frei, III, and Edmund A. Gehan The Department of Developmental Therapeutics [E. M.] and the Department of Biomathematics [E. A. G./, The University of Texas M. D. Anderson Hospital and Tumor Institute at Houston, Houston, Texas 77025 Summary whose progressive death rate from all causes is similar to that of a normal population of the same sex and age constitution." "We can speak of cure for Hodgkin's disease when in I would add that it should also be unassociated with time-probably a decade or so after treatment-there remains a continuing morbidity from the disease or its treatment. While group of disease-free survivors whose progressive death rate this excellent definition is quite acceptable for Hodgkin's from all causes is similar to that of a normal population of the disease (or for most cancers, for that matter), it has the major same age and sex constitution." Analysis of survival curves for limitation that it takes years to determine the cure rate of a patients with Hodgkin's disease indicates that even for patients given form of treatment. The rapid progress in therapeutic with Stage I and II disease there is excessive mortality per unit research has brought focus on the need for determining the time as compared to the control population for at least 10 probability of cure as early as possible. years after treatment. Thus, while the above definition is acceptable, the lag period required for the evaluation of Survival Data for Selected Other Cancers potentially curative treatment is very long. -
KAT Full Dissertation 12-6-10
Spontaneous Remission of Cancer: Theories from Healers, Physicians, and Cancer Survivors By Kelly Ann Turner A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Social Welfare in the Graduate Division of the University of California, Berkeley Committee in Charge: Professor Lorraine Midanik, Chair Professor Andrew Scharlach Professor Joan Bloom Fall 2010 Spontaneous Remission of Cancer: Theories from Healers, Physicians, and Cancer Survivors © 2010, all rights reserved by Kelly Ann Turner Abstract Spontaneous Remission of Cancer: Theories from Healers, Physicians, and Cancer Survivors by Kelly Ann Turner Doctoral of Philosophy in Social Welfare University of California, Berkeley Professor Lorraine Midanik, Chair BACKGROUND: Spontaneous Remission (SR) of cancer is defined as “the disappearance, complete or incomplete, of cancer without medical treatment, or with treatment that is considered inadequate to produce the resulting disappearance of disease symptoms or tumor” (O’Regan, 1995, p. 2). PURPOSE: This study sought to answer two questions: 1) What causative theories do alternative healers, physicians, and SR survivors propose for SR?; and, 2) Do SR survivors have a strong Sense of Coherence (SOC)? METHODS: Healers and physicians from 11 countries (n1=50) and SR survivors (n2=20) were interviewed in-depth; 17 of the 20 cancer survivors also completed an SOC scale. RESULTS: Six treatments that may elicit SR emerged frequently among both SR and Healer/Physician subjects: 1) Deepening one’s spirituality; 2) Trusting in intuition regarding health decisions; 3) Releasing negative and/or repressed emotions; 4) Feeling love/joy/happiness; 5) Changing one’s diet; and, 6) Taking herbal/vitamin supplements. -
Treating Acute Myeloid Leukemia (AML) If You've Been Diagnosed with Acute Myeloid Leukemia (AML), Your Cancer Care Team Will Discuss Your Treatment Options with You
cancer.org | 1.800.227.2345 Treating Acute Myeloid Leukemia (AML) If you've been diagnosed with acute myeloid leukemia (AML), your cancer care team will discuss your treatment options with you. Your options may be affected by the AML subtype, as well as certain other prognostic factors, as well as your age and overall state of health. How is acute myeloid leukemia treated? The main treatment for most types of AML is chemotherapy, sometimes along with a targeted therapy drug. This might be followed by a stem cell transplant. Other drugs (besides standard chemotherapy drugs) may be used to treat people with acute promyelocytic leukemia (APL). Surgery and radiation therapy are not major treatments for AML, but they may be used in special circumstances. ● Chemotherapy for Acute Myeloid Leukemia (AML) ● Targeted Therapy Drugs for Acute Myeloid Leukemia (AML) ● Non-Chemo Drugs for Acute Promyelocytic Leukemia (APL) ● Surgery for Acute Myeloid Leukemia (AML) ● Radiation Therapy for Acute Myeloid Leukemia (AML) ● Stem Cell Transplant for Acute Myeloid Leukemia (AML) Common treatment approaches The typical treatment approach for AML is different from the treatment approach for acute promyelocytic leukemia (APL). The response rates for treatment can vary based on the subtype of AML, as well as other factors. Treatment options might be different if the AML doesn't respond to the initial treatment or if it comes back later on. The treatment approach for children with AML can be slightly different from that used for adults. It's discussed separately in Treatment of Children With Acute Myeloid Leukemia 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 (AML). -
How Do We Define Success? Cure? Remission? Chronic Suppression? by Frank Mccormack, Md, Scientific Director
ourneys OUR COMPREHENSIVE JOURNAL ON LAM RESEARCH, PATIENT ADVOCACY, EDUCATION JAND AWARENESS PROVIDED BY THE LAM FOUNDATION SUMMER 2013 How Do We Define Success? Cure? Remission? Chronic Suppression? BY FRANK McCORMACK, MD, SCIENTIFIC DIRECTOR e have an effective treatment for she subsequently developed myelodysplasia and required a bone WLAM, sirolimus. We know that marrow transplant. There may be a lesson here for LAM as well. sirolimus does not cure LAM, however, More on that below. because it only seems to have beneficial We think that sirolimus is partially restoring cellular order effects on lung function while the drug and suppressing bad LAM cell behaviors-their tendency to move, is being taken. In most cases, it stabilizes invade and secrete VEGF-D and lung dissolving substances. Not rather than improves lung function, so it curing, not inducing remission, but suppressing. LAM cells seem does not meet the most rigorous definition to be shrinking and behaving, but not dying, on sirolimus. When of cure, that is, a “complete restoration of sirolimus is stopped VEGF-D levels again rise, AMLs increase in health”. Lance Armstrong’s course is a good example of a cure. size, and lung function decline resumes, suggesting the disease has Treatment completely eradicated his fatal, metastatic testicular been released from suppression. cancer and completely restored his health. We don’t think that Recently, on a trip to Los Angeles to talk about LAM, a scientist lung function in LAM, once lost, can be completely restored (at in the audience asked me if I was disappointed by the limitations least not in 2013). -
Prolonged Remission Maintenance in Acute Myeloid Leukaemia
544 BRITISH MEDICAL JOURNAL 27 AUGUST 1977 the thrush in our patient. Liver function tests during con- tion of the support given by the staff of The Royal Free Hospital and valescence showed no evidence of liver damage. the various health departments. In the early stage of the illness facilities were not available for Br Med J: first published as 10.1136/bmj.2.6086.544 on 27 August 1977. Downloaded from conducting haematological or biochemical studies safely, so efforts were concentrated on establishing the virological diagnosis; in the late stage of the illness, when provision had References been made for routine tests,16 they were not required for the 1 Martini, G A, Postgraduate Medical Jfournal, 1973, 49, 542. management of the patient, though they proved useful for 2 Gear, J S S, et al, British Medical,Journal, 1975, 4, 489. assessing the extent of damage during convalescence. For- 3Weekly Epidemiological Record, 1976, 51, 325. tunately there was no bleeding and the use of prophylactic 4Simpson, D, personal communication, 1977. heparin was not considered to be necessary. 5 Johnson, K M, et al, Lancet, 1977, 1, 569. 6 Bowen, E T W, et al, Lancet, 1977, 1, 571. Once the haemoglobin and white blood cell levels had returned " Pattyn, S, et al, Lancet, 1977, 1, 573. to normal plasmapheresis was performed to obtain a supply of 8 Emond, R T D, Postgraduate Medical Journal, 1976, 52, 563. convalescent serum. 9 British Medical Journal, 1976, 1, 64. 10 Bowen, E T W, British J7ournal of Experimental Pathology, 1969, 50, 400. -
Infections and Infectious Diseases: a Manual for Nurses and Midwives in the WHO European Region
Infections and infectious diseases A manual for nurses and midwives in the WHO EuropeanRegion World Health Organization Regional Office for Europe International Federation of Red Cross and Red Crescent Societies ABSTRACT There is an urgent need to re-establish basic infection control measures, which have been overlooked or played a less important role in controlling the spread of infections since the introduction of antibiotics in the 1940s. This manual has been written with the aim of developing the knowledge, skills and attitudes of nurses and midwives regarding infections and infectious diseases and their prevention and control. It is intended to be used as an interactive learning package for nurses and midwives in the WHO European region, specifically in eastern Europe. There are seven modules. Each module is in two parts: theory and practice. A workbook is provided separately, with opportunities for self-assessment through learning activities. A completed workbook is also available for each module to give further guidance to readers. Keywords INFECTION CONTROL INFECTIOUS DISEASES PREVENTION TREATMENT NURSING CARE © World Health Organization 2001 All rights in this document are reserved by the WHO Regional Office for Europe. The document may nevertheless be freely reviewed, abstracted, reproduced or translated into any other language (but not for sale or for use in conjunction with commercial purposes) provided that full acknowledgement is given to the source. For the use of the WHO emblem, permission must be sought from the WHO Regional Office. Any translation should include the words: The translator of this document is responsible for the accuracy of the translation. The Regional Office would appreciate receiving three copies of any translation. -
The Citadel Cannot Hold: Technologies Go Outside the Hospital, Patients and Doctors Too
The Citadel Cannot Hold: Technologies Go Outside the Hospital, Patients and Doctors Too JOHN D. STOECKLE Massachusetts General Hospital Boston he h o s p i t a l , o u r t r e a t m e n t institution for the care of the sick in bed, is being downsized. That is well known. Many hospitals have closed, and many that continue to Tfunction have reduced their beds as their admissions decrease. Mean while, ambulatory visits to physicians and the use of diagnostic and treatment technologies in out-of-hospital and home settings have in creased. The well-documented decline in hospital use and size has many interrelated explanations, which, however, are technical, clinical, and or ganizational; it is not a phenomenon that can be attributed either to in stitutional planning or to health care policies. Five explanations for the reduction in beds are notable: 1. The decentralization of diagnostic-treatment technologies to out- of-hospital sites. 2. The clinical substitution of quick diagnostic testing of the ambula tory patient for the longer diagnostic observation and testing of the patient hospitalized in bed. 3. The diminished use of hospital bed rest and the expanded use of out-of-hospital exercise and activity for treatment, convalescence, and rehabilitation of both acute and chronic disablements. The Milbank Quarterly, Vol. 73, No. 1, 1995 © 1995 Milbank Memorial Fund. Published by Blackwell Publishers, 238 Main Street, Cambridge, MA 02142, USA, and 108 Cowley Road, Oxford 0X 4 1JF, UK. 3 4 John D. Stoeckle 4. The corporate organization of hospital work that emphasizes process efficiency to reduce the lengths of stay in order either to achieve greater profits or to reduce costs. -
Chapter 28: Diabetes and Long-Term Care
Chapter 28 Diabetes and Long-Term Care Jennifer A. Mayfield, MD, MPH; Partha Deb, PhD; and D.E.B. Potter, MS SUMMARY ong-term care, which includes nursing fa- Medicaid contributed an average of $1,226 more per cilities and home health care, provides care diabetic resident in 1987 than per nondiabetic resi- to an increasing population of disabled, eld- dent. This was due, in part, to the higher rate of erly persons with diabetes. Nursing facili- eligibility for Medicaid coverage of diabetic com- Lties provide the majority of formal long-term care. pared with nondiabetic residents (62% versus 52%). Data from the Institutional Component of the 1987 National Medical Expenditure Survey (NMES-2) Diabetic residents have higher rates of acute and provide a profile of the demographics, health status, chronic complications of diabetes, resulting in health care use, and nursing facility expenditures of higher rates of expensive hospitalizations and death residents with and without diabetes. compared with nondiabetic residents. These compli- cations can be delayed, if not prevented, by appropri- In 1987, 389,000 residents of nursing facilities age ate preventive care. The care of diabetic residents is ≥55 years had diagnosed diabetes. About 18.3% of all complicated by age-associated changes and the num- nursing home residents age ≥55 years had been diag- ber of chronic conditions and disabilities in these nosed with diabetes, compared with 12.6% of the persons. Providing quality care for diabetic residents general population. Persons with diabetes age ≥55 in nursing facilities is hampered by staff shortages, years were twice as likely as nondiabetic persons to frequent staff turnover, poor pay, and lack of educa- reside in a nursing facility.